Denosumab marks Accord’s sixth biosimilar approval in Europe. The CHMP has issued a positive opinion for Denosumab, to be marketed as Osvyrti® and Jubereq®. Osvyrti® is Accord’s second osteoporosis biosimilar, following Sondelbay®. The CHMP’s endorsement paves the way for market…
